Use of complexes of tetrachloroplatinate with a diazo dye as antitumour agents

Abstract: Complexes having the structure of an ionically neutral complex of a tetrachloroplatinate (II) with a nitroaromatic azoic diazo nuclear dye are described which are cytotoxic to tumour cells in mammals and enhance the killing effect of radiation and heat.

Description: This invention relates to complexes of bivalent platinum and nuclear dyes useful in delaying growth of tumors in mammals and in enhancing the killing of tumor cells by radiation therapy and/or hyperthermia. Cis-diamminedichloroplatinum (II) and certain organic complexes of the tetrachloroplatinate dianion have long been known as anti-tumor drugs as well as enhancers of the effect of radiotherapy on tumors, Richmond et al., Radiation Research, Vol 71, 447-460 (1977); and mitochondrial dyes such as Rhodamine-123 have also been reported to be selectively retained by and selectively toxic toward carcinoma cells by Bernal et al., Science, Vol 222, 169-172 (1983). Complexes of tetrachloroplatinate with Rhodamine-123 and certain other mitochondrial dyes have been reported to have good anti-tumor activity in the absence of radiation; of these, the Rhodamine-123 complex has been indicated to be the most effective in enhancing cell killing by radiation because of its relatively low level of whole-mammal toxicity and its relatively high level of radiation enhancement. Teicher et al., Int. J. Rad. Onc. Biol. Phys., Vol 11, 937-941 (1985); Teicher et al., Ibid., Vol 13, 1217-1224 (1987); Teicher et al., Rad. Res., Vol. 109, 58-67 (1987); Teicher et al., Biochem. Pharmacol., Vol 35, 3365-3369 (1986). However, the generally accepted rule is that clinical hypoxic cell radiation sensitizers should be non-toxic at effective sensitizing concentrations; this has militated against clinical use of previously known dye complexes with platinum. We provide a complex having the structure of an ionically neutral complex of a tetrachloroplatinate (II) with a dye, together with a pharmacologically acceptable non-toxic carrier therefor characterised in that said complex has the structure: wherein R, R₁, R₂ and R₃ are each lower alkyl groups having 1-5 carbon atoms, and may be the same or different. We have found that complexes of the abovementioned structure are both effective anti-tumor agents in the absence of radiation and also effective sensitizers to or enhancers of subsequent radiation or heating, and have a high therapeutic index, as indicated by the wide range of dosage which is effective but non-lethal and the lack of toxicity to bone marrow. Most preferred is the complex made with the nuclear dye Fast Black, hereinafter referred to as Pt(Fast Black)₂. which has the composition shown above in which R, R₁. R₂, and R₃ are all methyl groups. The complexes can be made simply by adding a slight molar excess of the dye to potassium tetrachloroplatinate in water at room temperature and allowing the mixture to stand. The desired complex precipitates. The complex can be administered by percutaneous injection; when employed in conjunction with radiation or heat it is preferably administered within a few hours before exposure to radiation or heat although there is nothing critical about the time interval between the two. It can be administered in solution in any pharmacologically acceptable carrier. The effective dose may vary over a wide range, varying from 50 mg/kg of body weight up to the maximum tolerated dose (i.e. the LD₅₀) which is of the order of 600 mg/kg. The optimum dose in any case can be determined by routine tests and is far higher than the maximum tolerated dose for the dye alone. The following specific example is intended to illustrate the nature of the invention Example Fast Black Potassium Salt (Aldrich) (0.92g, 0.0022 mol.) was dissolved in water (15 ml.). To this solution was added a solution of potassium tetrachloroplatinate (0.42g, 0.001 mol.) in 10 ml. of water. A precipitate formed immediately, and after stirring for 30 minutes the precipitate was collected by suction filtration, washed with ice cold water (20 ml.), methanol (20 ml.), and diethyl ether (20 ml.). Yield of the complex Pt (Fast Black)₂ was 1.10 g (57% based on platinum). Analysis: Calc.: C 34.85%, H 2.48%, N 14.50%, Pt 20.20%. Found: C35.07%, H 2.48%, N 14.08%, pt 19.91%. 1.R. and U.V. absorption spectra and H-nmr data were consistent with the structure shown above. Anti-tumor activity of the complex prepared as described above was determined in vivo in mice by comparative tests against Fast Black dye alone and against Cis-diamminedichloroplatinum (CDDP) using the following procedure. Two different solid tumor cell lines were employed, Lewis Lung and FSaII, 2x10⁶ tumor cells being implanted i.m. into the legs of male C57BL/6J and C3H/He mice 8 to 10 weeks of age, respectively. The drugs were administered i.p. on day 7 after tumor implantation (when tumors were about 100 mm³ in volume), in solution (0.5%) in 0.9% phosphate-buffered saline as carrier. Tumor growth delay is reported in Table I below as the difference in number of days for the treated tumors to reach 500mm³ in volume and the number of days required for untreated control tumors to reach the same volume (n=14 in each group). Tumor volume was calculated as a hemiellipsoid. In the control animals, tumors reached the specified volume in 12-14 days. Anti-metastatic activity was determined by implanting Lewis Lung carcinoma cells in the legs of mice as described above, administering drugs in the doses indicated in Table II below, i.p. on day 7 after implantation and removing the lungs on day 20 followed by counting metastases. Control mice received no drug (n=14 in each group). The results were as follows: Effectiveness of the Pt (Fast Black)₂ complex as a radiosensitizer or radiation enhancer in vivo was determined in comparison with Fast Black alone and with misonidazole, a nitroimidazole enhancer, by measuring growth delay in mice. FSaII fibrosarcoma cells (2 x 10⁶ FSaII cells) were implanted in the legs of mice; the drug was administered i.p. when the tumor had grown to approximately 50mm³ in volume, using 0.9% phosphate buffered saline as carrier, as described above in the doses shown in Table 3 below. Fifteen minutes later radiation was delivered locally to the tumor bearing limb as a single dose of 10, 20, or 30 gray as indicated in the table. No anesthetic was used. The growth of each tumor was measured thrice weekly until it reached a volume of 500mm³. Each treatment group had 7 animals and the procedure was repeated 3 times. Tumor volume was calculated as a hemiellipsoid, and in the untreated control animals, tumors reached the specified volume in 14.0 days. The delay is reported in terms of the mean number of additional days beyond the control required for the tumors in each group to reach the specified volume. The results were as follows: The complex was also found to be effective in enhancing the killing effect of heat treatment (hyperthermia) in vivo . The procedure described in the preceding paragraph was carried out except that there was substituted for the single radiation dose a heat treatment by immersion of the tumor-bearing limb in a water bath at 44°C for 30 minutes to raise the tumor temperature to 43°C. The mean number of days delay (n=14) was as follows: Analysis of EMT6 cells exposed to the complex of the example showed that entry of platinum into the cells was approximately 100 times as great as in the case of exposure to Cis-diamminedichloroplatinum (II) at the same concentration and exposure time; exposure to potassium tetrachloroplatinate provided only very poor entry of platinum into the cells. Cytotoxicity assays on the well-established EMT6 mammary tumor cell line under normally oxygenated conditions and hypoxic conditions at both pH 7.40 and pH 6.45 showed Pt (Fast Black)₂ to be moderately cytotoxic, killing 1 log of hypoxic cells at 500µM for 1 hour and 1.5 logs of normally oxygenated cells at pH 7.4; at pH 6.45 however, the pH level expected in hypoxic areas in tumors, there were approximately 3.5 logs of cell kill in both normally oxic and hypoxic cells. The Pt (Fast Black)₂ complex of the example efficiently produces single strand breaks in DNA and associates with the DNA in such a way that the electrophoretic mobility of the DNA is altered and ethidium bromide binding is inhibited.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE A pharmaceutical composition comprising a complex having the structure of an ionically neutral complex of a tetrachloroplatinate (II) with a dye, together with a pharmacologically acceptable non-toxic carrier therefor characterised in that said complex has the structure: wherein R, R₁, R₂ and R₃ are each lower alkyl groups having 1-5 carbon atoms, and may be the same or different. A pharmaceutical composition according to in Claim 1, further characterised in that R, R₁, R₂, and R₃ are methyl groups. A pharmaceutical composition according to Claim 1 or Claim 2 in injectable form. A complex as defined in Claim 1 or Claim 2 for use in human or animal therapy as a cytotoxic agent or to increase susceptibility of tumour cells to killing, for example by radiation or heat. Use of a complex as defined in Claim 1 or Claim 2 for the manufacture of a medicament for use in human or animal therapy as a cytotoxic agent or to increase susceptibility of tumour cells to killing, for example by radiation or heat. A complex as defined in Claim 1 or Claim 2. Claims for the following Contracting States : ES, GR A method of forming a pharmaceutical composition, comprising the steps of forming an ionically neutral complex of a tetrachloroplatinate (II) with a dye, and combining said complex with a pharmacologically acceptable non-toxic carrier therefor, said dye having the structure: wherein R and R₁ are each lower alkyl groups having 1-5 carbon atoms, and may be the same or different. A method of forming a pharmaceutical composition according to Claim 1, further characterised in that R and R₁ are methyl groups. A method according to Claim 1 or Claim 2, further characterised in that said carrier is chosen such that said composition is in injectable form. A complex having the structure of: wherein R, R₁, R₂, and R₃ are each lower alkyl groups having 1-5 carbon atoms, and may be the same or different, for use in human or animal therapy as a cytotoxic agent or to increase susceptibility of tumour cells to killing, for example by radiation or heat. A complex as defined in Claim 4 wherein R, R₁, R₂ and R₃ are methyl groups, for use in human or animal therapy as a cytotoxic agent or to increase susceptibility of tumour cells to killing, for example by radiation or heat. Use of a complex having the structure: wherein R, R₁, R₂ and R₃ are each lower alkyl groups having 1-5 carbon atoms, and may be the same or different, for the manufacture of a medicament for use in human or animal therapy as a cytotoxic agent or to increase susceptibility of tumour cells to killing, for example by radiation or heat. Use of a complex as defined in Claim 6, wherein R, R₁, R₂ and R₃ are methyl groups, for the manufacture of a medicament for use in human or animal thereapy as a cytotoxic agent or to increase susceptibility of tumour cells to killing, for example by radiation or heat.

Inventors: TEICHER BEVERLY A, TEICHER, BEVERLY A.
Applicants: DANA FARBER CANCER INST INC, DANA-FARBER CANCER INSTITUTE, INC.
Application year: 1990
Main classification: A61K31
IPC codes: A61K41, A61K31, A61K33, A61P35